Background
==========

Thousands of human long non-coding RNAs (lncRNAs) have been identified and emerging studies have revealed that lncRNAs play important roles in a wide range of biological processes \[[@B1],[@B2]\] and diseases \[[@B3],[@B4]\]. However, functions of most human lncRNAs are still elusive. Functions of a lncRNA may be determined by loss- and gain-of-function biological experiments \[[@B5],[@B6]\]. However, this is not straightforward since it is difficult to knock down a lncRNA expressed as multiple isoforms. Alternatively, computational exploration of human lncRNA functions is helpful to guide further studies on lncRNAs.

Currently, computational investigation of lncRNA functions is still at its early development stage, since it is a considerable challenge due to the characteristics of lncRNAs, e.g., many lncRNA gene sequences are not conserved and do not contain conserved sequence motifs \[[@B7]\], which makes it difficult to infer potential functions of lncRNAs based on their sequences alone. In addition, few available molecular interaction data of new identified lncRNAs also hamper the lncRNA functional annotations \[[@B8],[@B9]\].

Since genes with similar expression patterns across multiple conditions may share similar functions \[[@B10]\] or be involved in related biological pathways \[[@B11]\], identifying protein-coding genes that are co-expressed with lncRNAs may help to assign functions to the lncRNAs. By analyzing lncRNA-mRNA co-expression pattern, Guttman et al. identified several sets of mouse lncRNAs associated with protein-coding gene sets of distinct GO functional categories \[[@B12]\]. In addition, two recent studies separately constructed a mouse co-expressed lncRNA-mRNA network using mouse microarray data and assigned functions to 340 and 1,625 mouse lncRNAs \[[@B13],[@B14]\].

Despite accumulating insights into the mouse lncRNA functions, more than 10,000 human lncRNAs remain to be functionally characterized. Firstly, given a single human lncRNA gene, it needs to be established whether it executes crucial biological functions. Secondly, given a set of human lncRNA genes such as differential lncRNAs between cancer and normal samples, it is an important downstream task to identify significantly enriched function terms. Thirdly, given an important functional term such as a Wnt signalling pathway, how to know which lncRNAs may be involved in the pathway.

Here, based on the expression correlation between lncRNAs and protein-coding genes inferred from RNA-seq data of 19 human normal tissues, we functionally annotated 9,625 human lncRNAs with significantly enriched functional terms among the co-expressed protein-coding genes, and developed a user-friendly web interface for the lncRNA community to obtain the lncRNAs associated with a specific functional term, the functional terms associated with a specific lncRNA, or to assign functions to a set of human lncRNAs of interest.

Methods
=======

Data sources
------------

We downloaded: (1) genomic coordinates of all human lncRNA genes and protein-coding genes from the GENCODE V15 \[[@B15]\], (2) paired-end RNA-Seq data of 19 human normal tissues from the Human Body Map 2 project (ArrayExpress accession no. E-MTAB-513) and another study (GEO accession no. GSE30554), (3) GO assignments for the proteins of the human UniProtKB Complete Proteome from the website of the Gene Ontology Project \[[@B16]\], (4) 4,380 human biological pathways from the ConsensusPathDB database which integrated 12 pathway databases \[[@B17]\].

Workflow of LncRNA2Function
---------------------------

The schematic workflow of lncRNA2Function is shown in Figure [1](#F1){ref-type="fig"}. Firstly, RNA-Seq reads sequenced in 19 human normal tissues were firstly mapped to human genome (hg19) using tophat with the default parameters \[[@B18]\], and expression values of all human lncRNA and protein-coding genes in the 19 tissues were computed using cufflinks with the default parameter \[[@B19]\]. Secondly, the Pearson Correlation Coefficients (PCC) of all lncRNA-mRNA gene pairs were computed, and a set of significantly co-expressed protein-coding genes was thus obtained for each human lncRNA (significant: the absolute value of the Pearson correlation coefficient \>0.9 and adjusted *P-value*\< 0.05). Thirdly, each lncRNA was functionally annotated with significantly enriched GO terms and biological pathways among the set of co-expressed protein-coding genes. Finally, a web interface was developed to facilitate researchers to browse or search the functions associated with a given lncRNA or lncRNAs associated with a specific function, or to functionally annotate a set of lncRNA genes of interest.

![**Schematic workflow of the LncRNA2Function**.](1471-2164-16-S3-S2-1){#F1}

GO and pathway enrichment analysis of human lncRNAs
---------------------------------------------------

Given a single human lncRNA gene, we obtained a set of protein-coding genes that were significantly co-expressed with the lncRNA. The lncRNA was then functionally annotated with significantly enriched GO and pathway terms among the set of co-expressed protein-coding genes. The enrichment analysis was separately executed for each term (denoted as T), and a *P-value*of each term was calculated by the hypergeometric test:
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Herein, *N*is the number of all protein-coding genes in human genome, *M*is the number of protein-coding genes that were annotated in the functional term T, *n*is the number of protein-coding genes that were significantly co-expressed with the lncRNA, and *m*is the number of protein-coding genes that were both significantly co-expressed with the lncRNA and annotated in the functional term T.

For each GO term, protein-coding genes directly belong to it as well as those belong to any of its offspring terms are all considered as its annotated genes. Since the statistical analysis is not appropriate to problems with small sample size, those GO and pathway terms with less than 5 annotated protein-coding genes and those lncRNAs with less than 5 co-expressed protein-coding genes were excluded form the enrichment analysis.

Given a set of human lncRNA genes of interest, LncRNA2Function first identify a set of protein-coding genes, each of which are significantly co-expressed with one or more of the given lncRNAs across 19 human normal tissues. Then, the set of lncRNAs are functionally annotated with the enriched GO and pathway terms among the set of co-expressed protein-coding genes. If researchers input a large number of lncRNAs, the LncRNA2Function may obtain thousands of co-expressed protein-coding genes, some of which are co-expressed with only one of the lncRNAs. To improve the accuracy of functional assignments to the set of lncRNAs, users can select the protein-coding genes that are co-expressed with at least *K*lncRNAs (the *K*can be assigned based on the size of the set of lncRNAs. The default *K*is 1).

There are two commonly used methods for controlling false discovery rate (FDR), the Benjamini-Yekutieli (BY) method \[[@B20]\] and the Benjamini-Hochberg (BH) method \[[@B21]\]. The former is suitable for positively related multiple hypothesis tests whereas the later is suitable for independent multiple hypothesis tests \[[@B22]\]. Since the hierarchical GO terms are often dependent, we chose the BY method to correct the *P-values*from the GO enrichment analysis, and the BH method to correct the *P-values*from the pathway enrichment analysis. The significant cut-off of corrected *P-value*was set as 0.05.

Results and discussion
======================

Functional annotations of a single human lncRNA
-----------------------------------------------

We obtained 5,232,299 significantly co-expressed pairs between 9,625 human lncRNA genes and 10,919 protein-coding genes. Each of the 9,625 lncRNAs was functionally annotated with significantly enriched GO terms and biological pathways among its co-expressed protein-coding genes. Consequently, we obtained 614,174 associations between 5,735 lncRNA genes and 3,890 GO terms, and 240,050 associations between 6,062 lncRNAs and 3,034 biological pathways. To understand the major functions of lncRNAs, we ranked GO biological processes and biological pathways according to the number of lncRNAs associated with each of them. Among the top ranked 200 GO biological processes and pathways, we found that lncRNAs play roles in many important biological processes, including defense response to bacterium, DNA packaging, meiosis, developmental process, metabolic process, cell cycle process, cell adhesion, cell differentiation, Jak-STAT signaling pathway and PI3K-Akt signaling pathway. A part of the enriched functions of lncRNAs have been validated by published studies \[[@B23]-[@B26]\].

Case studies
------------

Due to the lack of a large gold standard dataset of known human lncRNA functions, five well-studied lncRNAs were used as the examples to show the usefulness of LncRNA2Function.

Case study 1: HOTAIR
--------------------

The HOTAIR is a well-studied lncRNA. Rinn et al. found that the HOTAIR interacts with the Polycomb repressive complex 2 (PRC2) to modify chromatin and repress transcription of the HOX genes, which regulate development \[[@B27]\]. Niinuma et al. revealed that overexpression of HOTAIR was strongly associated with high-risk grade and metastasis among gastrointestinal stromal tumors (GIST) specimens, and knockdown of HOTAIR suppressed GIST cell invasiveness \[[@B28]\]. In addition, Gupta et al. demonstrated that the lncRNA HOTAIR is increased in expression in primary breast tumors and metastases, and enforced expression of HOTAIR in epithelial cancer cells leaded to altered histone H3 lysine 27 methylation, gene expression, and increased cancer invasiveness and metastasis in a manner dependent on PRC2. Conversely, loss of HOTAIR can inhibit breast cancer invasiveness \[[@B26]\].

To examine whether our LncRNA2Function can functionally annotate the lncRNA HOTAIR with development and metastasis-related functional terms, we applied the LncRNA2Function to the HOTAIR, and found that it was annotated with 99 GO biological processes and 33 pathways (The significant Corrected P-value cutoff is 0.05). Of the 99 GO biological processes, 77.8% (77/99) are involved in the development and morphogenesis as expected (The top 20 GO development-related biological processes are shown in Table [1](#T1){ref-type="table"}), and 9.1% (9/99) are involved in the cell invasion and metastasis, such as cell migration (GO:0016477), cell adhesion (GO:0007155), biological adhesion (GO:0022610) and cell motility (GO:0048870). In addition, Of the 33 biological pathways, 72.7% (24/33) are involved in the cell invasion and metastasis (Table [2](#T2){ref-type="table"}), such as focal adhesion, beta1 integrin cell surface interactions, NCAM1 interactions, Syndecan-1-mediated signaling events, PI3K-Akt signaling pathway and cell surface interactions at the vascular wall. Taken together, these results demonstrated that our LncRNA2Function can successfully recall the known functions of a well-studied lncRNA HOTAIR and suggested that it is applicable to infer potential functions of new identified lncRNAs.

###### 

The top 20 biological processes assigned to the development-regulating HOTAIR by LncRNA2Function.

  ----------------------------------------------------------------------------------------------------------------------
  GO term                                              Background frequency   Sample frequency   P-value    Corrected\
                                                                                                            P-value
  ---------------------------------------------------- ---------------------- ------------------ ---------- ------------
  System development                                   3253/20447             38/74              1.63E-12   2.37E-08

  Anatomical structure morphogenesis                   1884/20447             28/74              2.45E-11   7.10E-08

  Tissue development                                   1183/20447             23/74              1.33E-11   7.10E-08

  Embryonic skeletal system development                120/20447              10/74              1.73E-11   7.10E-08

  Anatomical structure development                     3717/20447             39/74              2.07E-11   7.10E-08

  Skeletal system development                          388/20447              14/74              1.01E-10   2.44E-07

  Organ morphogenesis                                  790/20447              18/74              2.89E-10   4.73E-07

  Multicellular organismal development                 3830/20447             38/74              2.56E-10   4.73E-07

  Developmental process                                4248/20447             40/74              2.93E-10   4.73E-07

  Organ development                                    2271/20447             29/74              3.63E-10   5.27E-07

  Skeletal system morphogenesis                        189/20447              10/74              1.54E-09   1.72E-06

  Multicellular organismal process                     5336/20447             44/74              1.39E-09   1.72E-06

  Single-multicellular organism process                5125/20447             43/74              1.51E-09   1.72E-06

  Extracellular matrix organization                    204/20447              10/74              3.23E-09   3.28E-06

  Extracellular structure organization                 205/20447              10/74              3.39E-09   3.28E-06

  Head development                                     52/20447               6/74               3.26E-08   2.96E-05

  Embryonic skeletal system morphogenesis              91/20447               7/74               3.86E-08   3.30E-05

  Single-organism developmental process                3161/20447             31/74              4.39E-08   3.54E-05

  Chordate embryonic development                       557/20447              13/74              9.05E-08   6.57E-05

  Embryo development ending in birth or egg hatching   564/20447              13/74              1.05E-07   7.23E-05
  ----------------------------------------------------------------------------------------------------------------------

###### 

The metastasis-associated HOTAIR was annotated with metastasis-related GO and pathway terms by LncRNA2Function.

  Database       Functional term                                  Background frequency   Sample frequency   P-value    Corrected P-value
  -------------- ------------------------------------------------ ---------------------- ------------------ ---------- -------------------
  GO             Locomotion                                       1022/20447             14/74              1.53E-05   0.003417
  GO             Cell migration                                   603/20447              10/74              6.07E-05   0.010887
  GO             Cell adhesion                                    790/20447              11/74              1.21E-04   0.020655
  GO             Biological adhesion                              792/20447              11/74              1.24E-04   0.020663
  GO             Cell motility                                    664/20447              10/74              1.34E-04   0.021695
  GO             Positive regulation of cell-cell adhesion        33/20447               3/74               2.30E-04   0.032376
  PID            Beta1 integrin cell surface interactions         75/20447               7/74               9.92E-09   2.22E-06
  Reactome       Extracellular matrix organization                102/20447              7/74               8.54E-08   9.57E-06
  KEGG           ECM-receptor interaction                         110/20447              7/74               1.44E-07   1.07E-05
  INOH           Integrin                                         141/20447              7/74               7.82E-07   4.01E-05
  Wikipathways   Focal Adhesion                                   203/20447              7/74               8.79E-06   2.46E-04
  KEGG           Focal adhesion                                   219/20447              7/74               1.44E-05   3.58E-04
  PID            Beta3 integrin cell surface interactions         47/20447               4/74               2.51E-05   5.61E-04
  PID            Syndecan-1-mediated signaling events             50/20447               4/74               3.21E-05   6.53E-04
  PID            Integrin cell surface interactions               58/20447               4/74               5.78E-05   0.001079
  PID            Integrins in angiogenesis                        73/20447               4/74               1.42E-04   0.002454
  Reactome       Integrin cell surface interactions               88/20447               4/74               2.93E-04   0.004373
  KEGG           PI3K-Akt signaling pathway                       361/20447              7/74               3.29E-04   0.004606
  Reactome       Cell surface interactions at the vascular wall   104/20447              4/74               5.53E-04   0.006566
  Reactome       Signaling by PDGF                                187/20447              5/74               5.86E-04   0.006566
  Reactome       NCAM1 interactions                               45/20447               3/74               5.79E-04   0.006566
  Reactome       NCAM signaling for neurite out-growth            72/20447               3/74               0.002268   0.023101
  Reactome       Platelet Adhesion to exposed collagen            22/20447               2/74               0.002848   0.025533
  PID            VEGFR3 signaling in lymphatic endothelium        25/20447               2/74               0.003673   0.031645
  Reactome       Basigin interactions                             26/20447               2/74               0.003969   0.032935
  KEGG           TGF-beta signaling pathway                       92/20447               3/74               0.004537   0.036298
  PID            Wnt signaling network                            29/20447               2/74               0.004924   0.038039
  Reactome       Degradation of the extracellular matrix          32/20447               2/74               0.005974   0.043169
  Reactome       Activation of Matrix Metalloproteinases          32/20447               2/74               0.005974   0.043169
  PID            Alpha4 beta1 integrin signaling events           34/20447               2/74               0.006725   0.046835

Case study 2: HCP5
------------------

The lncRNA HCP5 was found to be associated with AIDS \[[@B29]-[@B31]\]. Rodriguez-Novoa et al. analyzed a total of 245 HIV patients and found a good correlation between HLA-B\*5701 and HCP5 (negative and positive predictive values of 100% and 93%, respectively). Colombo et al. analyzed that 1,103 singles infected with human immunodeficiency virus (HIV) and concluded that HCP5 genotyping could serve as a simple screening tool for ABC-HSR, particularly in settings where sequence-based HLA typing is not available.

To assess whether the HCP5 can be correctly predicted to have immune-related functions, we applied our LncRNA2Function to it and found that HCP5 was annotated with 549 GO biological processes terms and 270 biological pathways. As expected, most of them are indeed immune system and response functional terms, which are strongly associated with the development of AIDS. The top 20 GO biological terms assigned to the HCP5 are shown in Table [3](#T3){ref-type="table"} while the top 20 biological pathways assigned to the HCP5 are shown in Table [4](#T4){ref-type="table"}.

###### 

The top 20 biological processes assigned to the AIDS-related lncRNA HCP5 by LncRNA2Function.

  ----------------------------------------------------------------------------------------------------------------
  GO term                                        Background frequency   Sample frequency   P-value    Corrected\
                                                                                                      P-value
  ---------------------------------------------- ---------------------- ------------------ ---------- ------------
  Immune system process                          1581/20447             208/458            1.0E-109   3.49E-105

  Immune response                                867/20447              148/458            1.57E-90   2.70E-86

  Defense response                               968/20447              144/458            2.37E-79   2.72E-75

  Regulation of immune system process            879/20447              131/458            1.16E-71   9.95E-68

  Regulation of immune response                  527/20447              105/458            9.62E-70   6.62E-66

  Response to stimulus                           6195/20447             312/458            9.35E-64   5.36E-60

  Cell activation                                557/20447              89/458             3.11E-50   1.53E-46

  Leukocyte activation                           344/20447              73/458             5.00E-50   2.15E-46

  Regulation of response to stimulus             2379/20447             173/458            1.23E-48   4.72E-45

  Positive regulation of immune system process   522/20447              84/458             1.39E-47   4.77E-44

  Response to stress                             2747/20447             181/458            4.76E-45   1.26E-41

  Signal transduction                            3612/20447             205/458            4.25E-42   1.04E-38

  Positive regulation of immune response         331/20447              63/458             4.17E-40   9.56E-37

  Cellular response to stimulus                  4596/20447             231/458            5.11E-40   1.10E-36

  Lymphocyte activation                          276/20447              58/458             1.81E-39   3.66E-36

  Innate immune response                         474/20447              72/458             6.13E-39   1.17E-35

  Positive regulation of response to stimulus    1154/20447             106/458            6.43E-37   1.16E-33

  T cell activation                              176/20447              46/458             5.40E-36   9.28E-33

  Single organism signaling                      4081/20447             208/458            1.23E-35   1.92E-32

  Immune response-regulating signaling pathway   218/20447              49/458             6.76E-35   1.01E-31
  ----------------------------------------------------------------------------------------------------------------

###### 

The top 20 pathways assigned to AIDS-related lncRNA HCP5 by our LncRNA2Function.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pahtway\   Pahtway name                                                               Background frequency   Sample frequency   P-value    Corrected P-value
  database                                                                                                                                   
  ---------- -------------------------------------------------------------------------- ---------------------- ------------------ ---------- -------------------
  Reactome   Immune System                                                              1177/20447             98/458             1.66E-30   2.14E-27

  KEGG       Natural killer cell mediated cytotoxicity                                  219/20447              38/458             6.00E-23   3.87E-20

  PID        Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell   104/20447              28/458             1.06E-22   4.54E-20

  Reactome   Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell   202/20447              35/458             3.36E-21   1.08E-18

  Reactome   Adaptive Immune System                                                     772/20447              66/458             4.68E-21   1.21E-18

  NetPath    TCR                                                                        252/20447              36/458             6.84E-19   1.47E-16

  KEGG       Chemokine signaling pathway                                                195/20447              30/458             7.56E-17   1.39E-14

  PID        Generation of second messenger molecules                                   15/20447               11/458             7.96E-16   1.28E-13

  KEGG       Osteoclast differentiation                                                 174/20447              27/458             2.20E-15   3.16E-13

  PID        TCR signaling in naive CD4+ T cells                                        80/20447               19/458             1.03E-14   1.32E-12

  PID        TCR signaling in naive CD8+ T cells                                        63/20447               17/458             2.63E-14   3.09E-12

  PID        IL12-mediated signaling events                                             81/20447               18/458             1.80E-13   1.94E-11

  KEGG       Cytokine-cytokine receptor interaction                                     291/20447              31/458             6.97E-13   6.42E-11

  Reactome   Innate Immune System                                                       542/20447              43/458             6.96E-13   6.42E-11

  KEGG       Hematopoietic cell lineage                                                 114/20447              20/458             9.26E-13   7.97E-11

  KEGG       T cell receptor signaling pathway                                          116/20447              20/458             1.30E-12   1.05E-10

  Reactome   Cell surface interactions at the vascular wall                             104/20447              19/458             1.62E-12   1.23E-10

  PID        Cell surface interactions at the vascular wall                             42/20447               13/458             4.26E-12   3.06E-10

  Reactome   Class A/1 (Rhodopsin-like receptors)                                       319/20447              31/458             7.85E-12   5.33E-10

  PID        Fc-epsilon receptor I signaling in mast cells                              64/20447               15/458             8.34E-12   5.38E-10
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

Case study 3: HULC
------------------

The lncRNA HULC is highly upregulated in liver cancer and plays an important role in tumorigenesis \[[@B32]\]. Depletion of HULC resulted in a significant deregulation of several genes involved in liver cancer \[[@B33]\], and colorectal carcinomas that metastasize to the livers but not to lymph nodes experience an up-regulation of HULC in all the samples tested (n = 8), with a strong-to-moderate expression in six out of eight \[[@B34]\].

To examine whether the HULC was predicted to have liver-related functions, we analyzed it using our lncRNA2Function. Expectedly, LncRNA2Function also works well to functionally annotate the HULC. The results showed that it was annotated with 373 GO biological processes and 383 biological pathways (the significant P-value cutoff is 0.05). Of the 373 GO biological processes and 383 pathways, over 80% are involved in the known liver-related biological functions, such as metabolic function, bile secretion, lipid transport and homeostasis, cholesterol homeostasis, regulation of blood coagulation, protein-lipid complex subunit organization, detoxification, Immune defense and complement activation. The Figure [2](#F2){ref-type="fig"} shows the top 25 GO functional terms assigned to the HULC, and the Table [5](#T5){ref-type="table"} shows the top 20 pathways enriched in protein-coding genes that are co-expressed with the liver-related lncRNA HULC.

![**The top 25 statistically significant enriched GO biological processes assigned to liver-related HULC are associated with the metabolic function of liver**.](1471-2164-16-S3-S2-2){#F2}

###### 

Top 20 pathways enriched in protein-coding genes that are co-expressed with the liver-related lncRNA HULC.

  -------------------------------------------------------------------------------------------------------------------------------------------
  Pahtway\       Pahtway name                                        Background frequency   Sample frequency   P-value    Corrected P-value
  database                                                                                                                
  -------------- --------------------------------------------------- ---------------------- ------------------ ---------- -------------------
  Reactome       Metabolism                                          1394/20447             128/390            6.17E-54   6.23E-51

  KEGG           Metabolic pathways                                  1256/20447             109/390            7.95E-43   4.01E-40

  KEGG           Retinol metabolism                                  69/20447               29/390             5.66E-32   1.91E-29

  KEGG           Complement and coagulation cascades                 87/20447               30/390             6.18E-30   1.56E-27

  EHMN           Androgen and estrogen biosynthesis and metabolism   90/20447               30/390             2.02E-29   4.07E-27

  Reactome       Biological oxidations                               151/20447              36/390             2.71E-29   4.55E-27

  KEGG           Drug metabolism - cytochrome P450                   76/20447               28/390             5.84E-29   8.41E-27

  KEGG           Metabolism of xenobiotics by cytochrome P450        87/20447               29/390             1.78E-28   2.24E-26

  KEGG           Chemical carcinogenesis                             86/20447               28/390             3.33E-27   3.74E-25

  EHMN           Tyrosine metabolism                                 113/20447              30/390             4.29E-26   4.33E-24

  EHMN           Xenobiotics metabolism                              54/20447               23/390             9.33E-26   8.56E-24

  Reactome       Metabolism of amino acids and derivatives           159/20447              32/390             1.09E-23   9.20E-22

  Wikipathways   metapathway biotransformation                       190/20447              34/390             2.43E-23   1.88E-21

  EHMN           Linoleate metabolism                                75/20447               24/390             2.81E-23   2.03E-21

  Wikipathways   cytochrome P450                                     68/20447               23/390             5.40E-23   3.63E-21

  Wikipathways   Complement and Coagulation Cascades                 60/20447               22/390             5.97E-23   3.77E-21

  EHMN           Leukotriene metabolism                              102/20447              26/390             2.87E-22   1.70E-20

  Reactome       Phase 1 - Functionalization of compounds            74/20447               23/390             5.01E-22   2.81E-20

  KEGG           Drug metabolism - other enzymes                     53/20447               20/390             2.85E-21   1.51E-19

  Reactome       Xenobiotics                                         15/20447               13/390             3.68E-21   1.86E-19
  -------------------------------------------------------------------------------------------------------------------------------------------

Case study 4: H19
-----------------

H19 is an important lncRNA that play roles in the infertility \[[@B35]\] and multiple cancers such as breast cancer \[[@B36],[@B37]\], cervical cancer \[[@B38]\], liver cancer \[[@B39],[@B40]\] and bladder cancer \[[@B41]\]. For example, Korucuoglu et al. revealed that H19 expression was lower in the infertility group as compared to the control group (4-fold change, P \< 0.0001), and Lottin et al. showed that over-expression of H19 transcript is associated with cells exhibiting higher tumorigenic phenotypes and promotes tumor progression.

We applied the LncRNA2Function to the lncRNA H19 and found that it was annotated with 6 GO biological processes and 31 biological pathways. The GO terms includes female pregnancy (GO: 0007565), estrogen biosynthetic process (GO:0006703), growth hormone receptor signaling pathway (GO:0060396), cellular response to growth hormone stimulus (GO:0071378) and JAK-STAT cascade involved in growth hormone signaling pathway (GO:0060397), which suggest that H19 may play roles in infertility or breast cancer by participating in these biological processes. In addition, the cancer-related lncRNA H19 was correctly annotated with many important caner pathways, such as PI3K-Akt signaling pathway, GPCR signaling-G alpha s Epac and ERK pathway, Nuclear signaling by ERBB4 pathway, Akt signaling pathway and JAK-STAT-Core cancer pathway. These results suggest that our LncRNA2Function correctly recall the known functions of H19.

Case study 5: PCA3
------------------

The lncRNA prostate cancer antigen 3 (PCA3) is a highly specific biomarker upregulated and plays crucial roles in prostate cancer (PCa) \[[@B42]-[@B45]\]. Clarke et al. found that up-regulation of two new PCA3 isoforms in PCa tissues improves discrimination between PCa and benign prostatic hyperplasia (BPH). In 2012, the US Food and Drug Administration approved the use of the lncRNA PCA3 for the detection of prostate cancer.

To test whether our LncRNA2Function can annotate the PCA3 with prostate-related functions, we applied the LncRNA2Function to the PCA3. LncRNA2Function first identified 77 protein-coding genes that are co-expressed with the PCA3 and then annotated it with only one pathway named \'Regulation of Androgen receptor activity\' (corrected P-value: 0.020385). This pathway has 62 genes, which includes 4 protein-coding genes that are co-expressed with the PCA3. These four genes are HOXB13, KLK3, KLK2 and SPDEF that have been validated to be useful in the diagnosis and monitoring of prostatic carcinoma and be suitable target for developing specific cancer therapies. Consequently, lncRNA2Function can correctly predict the functions of PCA3 by its co-expressed protein-coding genes.

Functional annotation for a set of human lncRNAs
------------------------------------------------

High-throughput genomic technologies like lncRNA microarray and RNA-Seq usually generate hundreds of candidate lncRNA genes of interest, such as a cluster of co-expressed lncRNA genes across multiple conditions or a set of differentially expressed lncRNAs between cancer and normal samples. To manually map each lncRNA to functional terms is by far a simple task. Therefore, how to identify significantly enriched functions among the set of lncRNAs is an important downstream task for interpreting high-throughput experimental data.

As a proof-of-concept, a set of liver-specific lncRNAs and a set of heart-specific lncRNAs inferred from RNA-Seq data of 19 human normal tissues were used as examples to show the functionality of our lncRNA2Function system in annotating a set of lncRNAs of interest, respectively. As expected, lncRNA2Function correctly assigned the functional terms to the two distinct sets of lncRNAs. Users can test these two sets or their own lncRNA sets at our \'LncRNA set analyzer\' web interface <http://mlg.hit.edu.cn/lncrna2function/lncrna_enrich.jsp>.

Web interface of LncRNA2Function
--------------------------------

To facilitate researchers to access the functional annotations of lncRNA genes, we developed a web interface named \'LncRNA annotation browser\', which is a user-friendly interface to browse or search lncRNAs associated with a specific functional term, or functional terms associated with a given lncRNA. To enable researchers to analyze a set of lncRNA genes of their interest, we implemented a web interface titled \'LncRNA set analyzer\', which can help investigators to annotate a set of lncRNAs with Gene Ontology and 4,380 biological pathways curated from 12 pathway databases. In addition, we developed a web interface titled \'LncRNA expression viewer\' to facilitate investigators to graphically view the expression dynamics of genes across multiple human normal tissues. Users can not only view expression value of a single lncRNA or protein-coding gene across 19 human normal tissues, but also simultaneously view the expression index of both lncRNA and protein-coding genes to learn about whether they are co-expressed across the 19 tissues. Furthermore, we provide a submission page that allows other researchers to submit known functional annotations of lncRNAs that are not documented in our LncRNA2Function system (Figure [3](#F3){ref-type="fig"}). They do not have to be an author on the original study to submit a record. Once approved by the submission review committee, the submitted records will be made available to the public in the coming release. LncRNA2Function is freely accessible at <http://mlg.hit.edu.cn/lncrna2function>.

![**Screenshot of web interface of LncRNA2Function**.](1471-2164-16-S3-S2-3){#F3}

Conclusions
===========

Thousands of human lncRNAs have been identified in recent several years, while the vast majority of the lncRNAs remain to be functionally characterized. In this study, we functionally annotate 9,625 human lncRNAs with the enriched functions among the protein-coding genes that are co-expressed with each lncRNA. Furthermore, we developed a web interface, which facilitates researchers to search the functions of a specific lncRNA or the lncRNAs associated with a given functional term, or annotate functionally a set of human lncRNAs of interest. The *lncRNA2Function*will become an important tool for investigating functions of human lncRNAs.
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